HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

160 Health International / Equity Capital Markets

<ul>
<li>160 Health collaborates with medical institutions and then get access to high-caliber medical professionals, which helps to attract patients/other business parties. So, its business model is B2B2C, similar to ClouDr.</li>
<li>However, ClouDr has much better performance than 160 Health, because ClouDr has established moat/barriers to more effectively monetize medical resources, while 160 Health is clearly lagging behind in this regard.</li>
<li>160 Health’s revenue mainly comes from sales of pharmaceutical and healthcare products, whose gross margin is very low. As the competition intensifies, the C-end customer acquisition cost would also increase.  </li>
</ul>


160 Health collaborates with medical institutions and then get access to high-caliber medical professionals, which helps to attract patients/other business parties. So, its business model is B2B2C, similar to ClouDr.
However, ClouDr has much better performance than 160 Health, because ClouDr has established moat/barriers to more effectively monetize medical resources, while 160 Health is clearly lagging behind in this regard.
160 Health’s revenue mainly comes from sales of pharmaceutical and healthcare products, whose gross margin is very low. As the competition intensifies, the C-end customer acquisition cost would also increase.  


Pre-IPO 160 Health - The Lack of Moat Has Led to Development Falling Far Short of Expectations

160 Health International (160HIL HK)

Pre-IPO 160 Health - The Lack of Moat Has Led to Development Falling Far Short of Expectations

160 Health’s B2B2C business model is logical, but rich medical resources can't be effectively translated into performance. Whichever business...

Xinyao (Criss) Wang